Cantillon Capital Management LLC Lowers Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Cantillon Capital Management LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 769,698 shares of the medical research company’s stock after selling 103,624 shares during the period. Thermo Fisher Scientific accounts for about 2.5% of Cantillon Capital Management LLC’s holdings, making the stock its 16th biggest position. Cantillon Capital Management LLC owned 0.21% of Thermo Fisher Scientific worth $378,330,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after purchasing an additional 288,296 shares in the last quarter. J. Stern & Co. LLP lifted its position in Thermo Fisher Scientific by 58,006.4% during the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares during the last quarter. State Street Corp grew its stake in Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Capital World Investors raised its position in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after buying an additional 718,669 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company’s stock worth $4,728,129,000 after acquiring an additional 26,425 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.1%

NYSE:TMO opened at $532.17 on Monday. The firm has a market capitalization of $197.77 billion, a P/E ratio of 29.26, a P/E/G ratio of 2.36 and a beta of 0.87. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company has a fifty day moving average of $484.57 and a 200 day moving average of $514.39. Thermo Fisher Scientific Inc. has a 52 week low of $403.36 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Activity

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on TMO shares. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Wolfe Research initiated coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective for the company. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. DZ Bank started coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Finally, Morgan Stanley reiterated an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.